Field Cancerization in NSCLC: A New Perspective on MicroRNAs in Macrophage Polarization.
Animals
Carcinoma, Non-Small-Cell Lung
/ etiology
Cell Transformation, Neoplastic
/ genetics
Disease Susceptibility
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
/ etiology
Macrophage Activation
/ genetics
Macrophages
/ immunology
MicroRNAs
/ genetics
RNA Interference
Tumor Microenvironment
/ immunology
field cancerization
lung cancer
macrophage polarization
miRNA
tumor microenvironment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Jan 2021
13 Jan 2021
Historique:
received:
13
12
2020
revised:
07
01
2021
accepted:
08
01
2021
entrez:
16
1
2021
pubmed:
17
1
2021
medline:
10
4
2021
Statut:
epublish
Résumé
Lung cancer is currently the first cause of cancer-related death. The major lung cancer subtype is non-small cell lung cancers (NSCLC), which accounts for approximatively 85% of cases. The major carcinogenic associated with lung cancer is tobacco smoke, which produces long-lasting and progressive damage to the respiratory tract. The progressive and diffuse alterations that occur in the respiratory tract of patients with cancer and premalignant lesions have been described as field cancerization. At the level of tumor cells, adjacent tumor microenvironment (TME) and cancerized field are taking place dynamic interactions through direct cell-to-cell communication or through extracellular vesicles. These molecular messages exchanged between tumor and nontumor cells are represented by proteins, noncoding RNAs (ncRNAs) and microRNAs (miRNAs). In this paper, we analyze the miRNA roles in the macrophage polarization at the level of TME and cancerized field in NSCLC. Identifying molecular players that can influence the phenotypic states at the level of malignant cells, tumor microenvironment and cancerized field can provide us new insights into tumor regulatory mechanisms that can be further modulated to restore the immunogenic capacity of the TME. This approach could revert alterations in the cancerized field and could enhance currently available therapy approaches.
Identifiants
pubmed: 33451052
pii: ijms22020746
doi: 10.3390/ijms22020746
pmc: PMC7828565
pii:
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Competitiveness Operational Program, 2014-2020
ID : 35/01.09.2016
Références
J Biol Chem. 2012 Jun 22;287(26):21816-25
pubmed: 22549785
Liver Int. 2018 Jan;38(1):125-135
pubmed: 28618167
BMC Cancer. 2019 Nov 14;19(1):1103
pubmed: 31727002
Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):331-43
pubmed: 12702543
Cancer Prev Res (Phila). 2017 Nov;10(11):651-659
pubmed: 28877936
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
Biomark Insights. 2018 Feb 06;13:1177271918755391
pubmed: 29449774
J Natl Cancer Inst. 1997 Sep 17;89(18):1366-73
pubmed: 9308707
Int J Oncol. 2006 Oct;29(4):745-52
pubmed: 16964372
Cancer Res. 2000 Sep 15;60(18):5074-9
pubmed: 11016631
Front Oncol. 2019 Oct 09;9:1029
pubmed: 31649886
Life Sci. 2020 Aug 15;255:117826
pubmed: 32450163
Lung Cancer. 2008 Dec;62(3):309-15
pubmed: 18486989
Clin Cancer Res. 1999 Aug;5(8):2025-34
pubmed: 10473082
Biomed Res Int. 2018 Jun 5;2018:6075403
pubmed: 29967776
Surg Pathol Clin. 2016 Sep;9(3):353-78
pubmed: 27523966
Cancer Discov. 2016 Mar;6(3):235-46
pubmed: 26865249
Oncol Rep. 2015 Dec;34(6):3088-96
pubmed: 26398698
PLoS One. 2015 Mar 30;10(3):e0121323
pubmed: 25822850
Cell Immunol. 2019 Sep;343:103729
pubmed: 29397066
Mol Cancer. 2019 Mar 30;18(1):65
pubmed: 30927919
J Clin Invest. 2014 Apr;124(4):1446-53
pubmed: 24691479
J Biol Chem. 2016 Jan 1;291(1):149-59
pubmed: 26527689
Nat Rev Genet. 2016 Jan;17(1):47-62
pubmed: 26666209
Cell Metab. 2007 Aug;6(2):137-43
pubmed: 17681149
Oncogene. 2017 Aug 24;36(34):4929-4942
pubmed: 28436951
Cancer Lett. 2015 Nov 1;368(1):7-13
pubmed: 26276713
Clin Cancer Res. 2017 Jun 1;23(11):2891-2904
pubmed: 27903673
N Engl J Med. 1961 Aug 10;265:253-67
pubmed: 13685078
Chem Res Toxicol. 2005 Feb;18(2):95-110
pubmed: 15720112
EMBO Mol Med. 2017 Sep;9(9):1244-1262
pubmed: 28674080
Int J Mol Sci. 2015 Oct 05;16(10):23651-67
pubmed: 26445043
J Immunol. 2014 Jun 1;192(11):5343-5353
pubmed: 24771857
Cancer Prev Res (Phila). 2014 Feb;7(2):255-65
pubmed: 24346345
Oncol Lett. 2016 Mar;11(3):1738-1744
pubmed: 26998070
Nat Rev Cancer. 2003 Oct;3(10):733-44
pubmed: 14570033
Mol Med Rep. 2019 Jun;19(6):4935-4945
pubmed: 31059086
Toxicol Sci. 2018 Jun 1;163(2):454-465
pubmed: 29471534
Cell Mol Life Sci. 2018 Oct;75(19):3539-3551
pubmed: 30030592
Nat Rev Immunol. 2011 Oct 25;11(11):750-61
pubmed: 22025054
Eur J Cancer. 2013 Feb;49(3):604-15
pubmed: 23099007
Int J Mol Sci. 2019 Mar 31;20(7):
pubmed: 30935143
Int J Mol Sci. 2020 Mar 20;21(6):
pubmed: 32245099
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Nat Rev Cancer. 2019 Jan;19(1):9-31
pubmed: 30532012
Oncol Lett. 2017 May;13(5):3247-3252
pubmed: 28521431
Cancer Res. 2010 Jul 15;70(14):5728-39
pubmed: 20570887
Clinics (Sao Paulo). 2011;66(11):1879-86
pubmed: 22086517
Cancer Cell. 2013 Mar 18;23(3):277-86
pubmed: 23518347
Annu Rev Pathol. 2006;1:331-48
pubmed: 18039118
Clin Chest Med. 2020 Mar;41(1):1-24
pubmed: 32008623
J Immunol. 2018 Jan 1;200(1):347-354
pubmed: 29141863
J Cell Physiol. 2016 Jan;231(1):120-9
pubmed: 26032086
Adv Exp Med Biol. 2017;1036:51-64
pubmed: 29275464
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
Cell Metab. 2006 Jul;4(1):13-24
pubmed: 16814729
Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):406-14
pubmed: 25465802
Nat Immunol. 2016 Jan;17(1):34-40
pubmed: 26681460
Front Immunol. 2017 Nov 24;8:1625
pubmed: 29225600
Cancer Cell Int. 2020 Jul 11;20:303
pubmed: 32675943
Lung Cancer. 2000 Nov;30(2):83-9
pubmed: 11086201
Oncotarget. 2016 May 17;7(20):29275-86
pubmed: 27086911
Mol Ther. 2018 Feb 7;26(2):568-581
pubmed: 29292163
PLoS One. 2019 Dec 26;14(12):e0226553
pubmed: 31877149
Funct Integr Genomics. 2020 Jan;20(1):17-28
pubmed: 31267263
Mol Aspects Med. 2019 Dec;70:33-56
pubmed: 31558293
Oncol Rep. 2017 Jun;37(6):3543-3553
pubmed: 28498428
Trends Immunol. 2013 Jul;34(7):350-9
pubmed: 23498847
J Natl Cancer Inst. 2017 Jul 1;109(7):
pubmed: 28376183
Cancer. 2014 Jul 1;120(13):1914-6
pubmed: 24687615
J Exp Clin Cancer Res. 2020 Apr 16;39(1):67
pubmed: 32299469
J Mol Med (Berl). 2013 Apr;91(4):431-7
pubmed: 23519402
Nat Cell Biol. 2011 Dec 18;14(2):159-67
pubmed: 22179046
Int J Cancer. 2019 Jun 1;144(11):2746-2761
pubmed: 30426475
Oncogene. 2011 Jan 6;30(1):106-16
pubmed: 20818420
Front Oncol. 2020 Apr 08;10:486
pubmed: 32322559
Lung Cancer. 2011 Nov;74(2):188-96
pubmed: 21601305
Adv Exp Med Biol. 2015;889:153-77
pubmed: 26659001
J Natl Cancer Inst. 2009 Apr 15;101(8):541-3
pubmed: 19351914
Cancer Metastasis Rev. 2016 Mar;35(1):75-91
pubmed: 27018053
J Clin Invest. 1997 Oct 15;100(8):2133-7
pubmed: 9329980
Cancer. 1953 Sep;6(5):963-8
pubmed: 13094644
Am J Respir Crit Care Med. 2016 Jan 15;193(2):116-30
pubmed: 26583808
Chem Rev. 1968 Apr;68(2):153-207
pubmed: 4868017
Adv Exp Med Biol. 2014;816:1-23
pubmed: 24818717
Oncotarget. 2016 May 31;7(22):32421-32
pubmed: 27107415
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Cancer Cell Int. 2007 Mar 15;7:2
pubmed: 17362521
BMC Cancer. 2010 Mar 25;10:112
pubmed: 20338029
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Biomed Res Int. 2016;2016:1428271
pubmed: 27247934
Nat Rev Cancer. 2018 Jan;18(1):19-32
pubmed: 29217838
Br J Cancer. 1996 Jan;73(2):203-9
pubmed: 8546907
Cell Mol Biol Lett. 2019 Apr 27;24:28
pubmed: 31061665
Cancer Res. 2016 Jul 1;76(13):3676-83
pubmed: 27216194
J Cancer. 2019 Aug 7;10(19):4574-4587
pubmed: 31528221
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
Biochim Open. 2017 Jan 05;4:8-18
pubmed: 29450136
Proc Am Thorac Soc. 2012 May;9(2):38-42
pubmed: 22550239
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Hiroshima J Med Sci. 2000 Jun;49(2):109-16
pubmed: 10920577
Breast Cancer. 2017 Jul;24(4):521-527
pubmed: 28477068
Cancer Lett. 1996 May 15;103(1):115-21
pubmed: 8616804
Cancer Lett. 2018 Oct 28;435:80-91
pubmed: 30098399
Biomedicines. 2020 Apr 13;8(4):
pubmed: 32294932
Cancer Biol Ther. 2017 Mar 4;18(3):142-151
pubmed: 28106481
Mol Cancer. 2019 Mar 30;18(1):57
pubmed: 30925935
J Thorac Cardiovasc Surg. 2015 May;149(5):1404-14.e4
pubmed: 25813410
J Exp Clin Cancer Res. 2019 Feb 8;38(1):62
pubmed: 30736829
J Biol Chem. 2004 Sep 17;279(38):40209-19
pubmed: 15210690
Cancer Res. 2018 Aug 15;78(16):4586-4598
pubmed: 29880482
Int J Cancer. 2020 Feb 1;146(3):781-790
pubmed: 30977121
Transl Oncol. 2019 Dec;12(12):1533-1538
pubmed: 31473370
Oncogene. 1999 Jan 21;18(3):643-50
pubmed: 9989814
FASEB J. 2019 Jan;33(1):545-556
pubmed: 30004795
Int J Mol Sci. 2019 Dec 05;20(24):
pubmed: 31817513
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
J Pathol. 2014 Nov;234(3):296-301
pubmed: 25046364
Nano Lett. 2018 Jun 13;18(6):3571-3579
pubmed: 29722542
Eur J Pharmacol. 2020 Jul 5;878:173105
pubmed: 32278855
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Aging (Albany NY). 2020 May 18;12(10):9380-9404
pubmed: 32420903
Cancer Manag Res. 2020 Feb 12;12:1079-1088
pubmed: 32104088
Chem Res Toxicol. 2016 Oct 17;29(10):1662-1678
pubmed: 27641760
Cancers (Basel). 2019 Apr 30;11(5):
pubmed: 31052265
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Trends Cancer. 2019 Dec;5(12):822-834
pubmed: 31813459
Gut. 2020 Jul;69(7):1283-1293
pubmed: 31744909
Cancer Res. 2002 Apr 15;62(8):2370-7
pubmed: 11956099
Cell Death Dis. 2014 Jan 30;5:e1034
pubmed: 24481448
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Clin Cancer Res. 2000 Jul;6(7):2604-10
pubmed: 10914700
Cancer Lett. 2020 Sep 28;488:1-8
pubmed: 32473240
Nat Rev Cancer. 2019 Jun;19(6):349-358
pubmed: 31024081
Cancer Res. 2003 Apr 15;63(8):1727-30
pubmed: 12702551